Advertisement

Search Results

Advertisement



Your search for Janice Dutcher, MD,Janice Dutcher, MD matches 1 pages

Showing 1 - 1


kidney cancer

Results of AXIS Trial Indicate a Significant Improvement over Historical Survival Data in Renal Cell Carcinoma 

The phase III open-label AXIS trial comparing axitinib (Inlyta) vs sorafenib (Nexavar) as second-line treatment for metastatic renal cell carcinoma has shown a significant difference in median progression-free survival (8.3 months in the axitinib group vs 5.7 months in the sorafenib group; hazard...

Advertisement

Advertisement




Advertisement